Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 2/20 | 0.66 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.66 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.66 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.66 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.66 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.66 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.66 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.47 |
| ▸ | MGLL | Q99685 | 3/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.45 |
| ▸ | HRH1 | P35367 | 1/20 | 0.45 |
| ▸ | CCR3 | P51677 | 1/20 | 0.45 |
| ▸ | PRSS12 | P56730 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1806630 | 0.84 | HRH3 (0.64) | HRH3KMT2AKCNH2MGLLMAPT | |
| SCHEMBL1808860 | 0.82 | MGLL (0.68) | HRH3KMT2AEPHX2MGLLCYP2C9 | |
| SCHEMBL5792309 | 0.82 | GRIN2D (0.64) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL1811688 | 0.82 | GHSR (0.53) | HRH3 | |
| SCHEMBL1807533 | 0.81 | CHRNA7 (0.53) | HRH3CCR3 | |
| SCHEMBL1811990 | 0.81 | NPC1 (0.61) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL1806499 | 0.80 | HRH3 (0.55) | HRH3KMT2AEPHX2MGLLCYP2C9 | |
| SCHEMBL1809885 | 0.80 | FASN (0.49) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL4576874 | 0.80 | GRIN2D (1.00) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL4577792 | 0.80 | GRIN2D (0.72) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9051296-B2 | Aryl carboxamide derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2015-06-09 | — | — | US | claimed |
| US-20120232052-A1 | ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2012-09-13 | — | — | US | claimed |
| WO-2011058766-A1 | ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2011-05-19 | — | — | WO | claimed |
| US-9051296-B2 | Aryl carboxamide derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2015-06-09 | — | — | US | disclosed |
| US-9051296-B2 | Aryl carboxamide derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2015-06-09 | — | — | US | disclosed |
| US-20120232052-A1 | ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2012-09-13 | — | — | US | disclosed |
| US-20120232052-A1 | ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2012-09-13 | — | — | US | disclosed |
| WO-2011058766-A1 | ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2011-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232052-A1 | ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS | SCN1B, SCN1A, SCN2B | GRIN2D 480/4885GRIN3B 278/4885GRIN1 140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.